Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Current pharmacotherapy of schizophrenia remains unsatisfactory with little hope for complete functional restoration in patients once the disease has developed. A preventive approach based on intervention in the prodromal stage of the disease aiming to preserve functional integrity by halting the progress of the disease is therefore extremely attractive. Here, we investigated the effects of preventive antipsychotic or antidepressant drug treatment in a well-established neurodevelopmental mouse model of multiple schizophrenia-related abnormalities. Pregnant mice on gestation day 9 were exposed to the viral mimic polyriboinosinic-polyribocytidylic acid (2 mg/kg, intravenously) or corresponding vehicle treatment, and the resulting offspring from both prenatal treatment conditions were subjected to chronic antipsychotic (haloperidol or clozapine), antidepressant (fluoxetine), or placebo treatment during the periadolescent stage of development. The effects of the preventive pharmacotherapy on behavioral and pharmacological functions were then investigated in adulthood using paradigms relevant to schizophrenia, namely prepulse inhibition, latent inhibition, and sensitivity to psychostimulant drugs. We show that periadolescent treatment with the reference antipsychotic and antidepressant drugs can successfully block the emergence of multiple psychosis-related behavioral and pharmacological abnormalities in subjects predisposed to adult brain pathology by exposure to prenatal immune challenge. At the same time, however, our study reveals numerous negative influences of the early pharmacological intervention on normal behavioral development in control subjects. Hence, even though preventive pharmacotherapy may be beneficial in individuals with predisposition to psychosis-related brain dysfunctions, chronic antipsychotic or antidepressant drug treatment in false-positive subjects is associated with substantial risk for long-term behavioral disturbances in adulthood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The adolescent brain and age-related behavioral manifestations
Spear, L. P. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(00)00014-2 · Cited by 5,433 · cited 1×
“However, this possibility is not at all surprising because prodromal-based pharmacological intervention in humans is often initiated during periadolescence or early adolescence, which represents a time window of significant ongoing brain development and maturation.(43)”
BackgroundMaternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 3×
“One of the critical pharmacological abnormalities in schizophrenia and other psychosis-related disorders is enhanced sensitivity to psychostimulant drugs, including dopamine receptor agonists and N-methyl-D-aspartate (NMDA) receptor antagonists.(29,30,38,39) Prenatal immune activation by PolyI:C in rodents can success…”
BackgroundPsychosis prediction: 12-month follow up of a high-risk ("prodromal") group
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, P. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00167-6 · Cited by 1,136
Diagnosing schizophrenia in the initial prodromal phase
Klosterkötter, J., Hellmich, M., Steinmeyer, E. M., & Schultze-Lutter, F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.2.158 · Cited by 1,049
Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring
Shi, L., Fatemi, S. H., Sidwell, R. W., & Patterson, P. H. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00297.2003 · Cited by 1,025
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“macological intervention, given that the pharmacology of HAL, CLZ, and FLX can be readily distinguished, at least in part, by their specific neurochemical activities and receptor affinities.(41,42)”
BackgroundEffects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671 · cited 1×
“were selected based on previous drug administration protocols using regular drinking bottles in mice.(31,32) HAL was obtained from Janssen-Cilag (Baar, Switzerland) in the form of ampoules consisting of 5 mg of HAL in 1 ml of solvent containing minimal amounts of lactic acid; it was further diluted in regular tap wate…”
MethodMcGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556 · cited 1×
“would have been satisfactory even in the absence of any medication.(8,9,16,17) Our experimental design is expected to yield results devoid of such interpretative Table 4.”
BackgroundTowards an immuno-precipitated neurodevelopmental animal model of schizophrenia
Meyer, U., Feldon, J., Schedlowski, M., & Yee, B. K. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.10.012 · Cited by 494 · cited 3×
“by measuring locomotor reaction to the acute drug exposure in the open field as described previously.(22,25,26) Fig.”
MethodSelf-citation
Research works printed but not linked: 37
- 1996, Schizophrenia Bulletin, 22, 327, 10.1093/schbul/22.2.327 · DOI · Paper page
- Cornblatt, 2002, Schizophrenia research, 54, 177, 10.1016/S0920-9964(01)00365-6 · DOI · Paper page
- Ruhrmann, 2005, European psychiatry : the journal of the Association of European Psychiatrists, 20, 1, 10.1016/j.eurpsy.2004.11.001 · DOI · Paper page
- Woods, 2003, Biological psychiatry, 54, 453, 10.1016/S0006-3223(03)00321-4 · DOI · Paper page
- 2007, The British Journal of Psychiatry, 51, s96
- McGlashan, 2003, Schizophrenia research, 61, 7, 10.1016/S0920-9964(02)00439-5 · DOI · Paper page
- McGlashan, 2006, American Journal of Psychiatry, 163, 790, 10.1176/appi.ajp.163.5.790 · doi:10.1176/appi.ajp.163.5.790 · Paper page
- Cornblatt, 2007, The Journal of clinical psychiatry, 68, 546, 10.4088/JCP.v68n0410 · DOI · Paper page
- Cornblatt, 2001, Schizophrenia research, 51, 31, 10.1016/S0920-9964(01)00236-5 · DOI
- McGlashan, 2001, Schizophrenia research, 51, 47, 10.1016/S0920-9964(01)00238-9 · DOI
- 2006, Schizophrenia Bulletin, 32, 166, 10.1093/schbul/sbj007 · DOI · Paper page
- Yung, 1998, The British Journal of Psychiatry, 172, 14, 10.1192/S0007125000297602 · DOI · Paper page
- BLOCK, 2006, American Journal of Psychiatry, 163, 1838, 10.1176/appi.ajp.163.10.1838 · doi:10.1176/appi.ajp.163.10.1838
- Fusar-Poli, 2007, Lancet, 370, 1746, 10.1016/S0140-6736(07)61732-2 · DOI
- Lee, 2005, CNS drugs, 19, 193, 10.2165/00023210-200519030-00002 · DOI
- Tenn, 2005, Biological psychiatry, 57, 586, 10.1016/j.biopsych.2004.12.013 · DOI
- 2003, 3, 289, 10.1016/S1566-2772(03)00089-6 · DOI
- Zuckerman, 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 28, 1778, 10.1038/sj.npp.1300248 · DOI · Paper page
- Meyer, 2006, Experimental brain research. Experimentelle Hirnforschung. Exp rimentation c r brale, 173, 243, 10.1007/s00221-006-0419-5 · DOI
- Meyer, 2008, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 33, 441, 10.1038/sj.npp.1301413 · DOI · Paper page
- Ozawa, 2006, Biological psychiatry, 59, 546, 10.1016/j.biopsych.2005.07.031 · DOI · Paper page
- Laruelle, 1999, Biological psychiatry, 46, 56, 10.1016/S0006-3223(99)00067-0 · DOI · Paper page
- Dunstan, 1979, Journal of neural transmission, 44, 187, 10.1007/BF01253062 · doi:10.1007/bf01253062
- Yee, 2005, Behavioural brain research, 163, 265, 10.1016/j.bbr.2005.05.013 · DOI
- 2001, 156, 234, 10.1007/s002130100810 · DOI · Paper page
- 2003, 169, 257, 10.1007/s00213-002-1313-x · DOI · Paper page
- 2005, Schizophrenia Bulletin, 31, 139, 10.1093/schbul/sbi005 · DOI · Paper page
- 1987, 91, 415, 10.1007/BF00216006 · DOI · Paper page
- Lahti, 1995, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 13, 9, 10.1038/sj.npp.1380271 · DOI · Paper page
- DeVane, 1999, Cellular and molecular neurobiology, 19, 443, 10.1023/A:1006934807375 · DOI
- 2000, 148, 83, 10.1007/s002130050028 · DOI · Paper page
- 2003, Journal of Pharmacology and Experimental Therapeutics, 305, 625, 10.1124/jpet.102.046987 · DOI · Paper page
- Perez-Costas, 2008, Journal of neural transmission, 115, 745, 10.1007/s00702-007-0004-5 · DOI
- de Oliveira, 1996, Journal of clinical pharmacy and therapeutics, 21, 229, 10.1111/j.1365-2710.1996.tb01143.x · DOI
- Brown, 2002, Mental retardation and developmental disabilities research reviews, 8, 51, 10.1002/mrdd.10004 · DOI · Paper page
- 2006, Schizophrenia Bulletin, 32, 200, 10.1093/schbul/sbj052 · DOI · Paper page
- Patterson, 2007, Science, 318, 576, 10.1126/science.1150196 · DOI · Paper page
Cited by
Immune involvement in schizophrenia and autism: Etiology, pathology and animal models
Patterson, P. H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.12.016 · Cited by 766
The environment and susceptibility to schizophrenia
Brown, A. S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.003 · Cited by 664
Prenatal Poly(I:C) Exposure and Other Developmental Immune Activation Models in Rodent Systems
Meyer, U. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.011 · Cited by 626
Self-citationBoksa, P. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.03.005 · Cited by 603
“…et al., 2007) and increases in MK801- and amphetamine- or methamphetamine-induced locomotion (Zuckerman et al., 2003; Zuckerman and Weiner, 2005; Meyer et al., 2008b,c,d,e; Ozawa et al., 2006) due to prenatal poly IC exposure; these changes are thought to reflect pathophysiological changes…”
InfluentialAltering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Metadata
- Authors
- Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M. J., & Feldon, J.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-08
- Volume
- 36
- Issue
- 3
- Pages
- 607-623
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2171206543
- Cited by
- 115
- References
- 13
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia. https://app.cochat.ai/papers/10.1093/schbul/sbn131
- The paper
- Meyer, U., Spoerri, E., Yee, B. K., Schwarz, M. J., & Feldon, J. (2010). Evaluating Early Preventive Antipsychotic and Antidepressant Drug Treatment in an Infection-Based Neurodevelopmental Mouse Model of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbn131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.